Literature DB >> 33551353

Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies.

Xiaoding Shen1, Qianyi Wan1, Rui Zhao1, Yutao Wu2, Yong Wang1, Yaping Cui1, Xiangnan Su1, Xiaoting Wu3.   

Abstract

BACKGROUND AND AIM: Accumulating evidence indicates a plausible association between inflammatory bowel diseases and the risk of adverse health outcomes. However, the conclusions are inconsistent. We aimed to perform an umbrella review of meta-analyses to appraise and grade the evidence of the association between inflammatory bowel diseases and the risk of adverse health outcomes.
METHODS: Meta-analyses of observational studies that examined the associations between inflammatory bowel disease and the risk of adverse health outcomes in PubMed, EMBASE, and Web of Science were screened.
RESULTS: This umbrella review identified 25 meta-analyses, which yielded 123 effect estimates for 60 unique putative health outcomes. Patients with inflammatory bowel diseases had a higher risk of adverse health outcomes, including multiple cancers, cardiovascular disease, adverse pregnancy outcomes, adverse oral outcomes, and other adverse events. Moreover, inflammatory bowel diseases caused greater harm to health based on the presented evidence. However, none of the evidence was classified as "high" quality, only 15% was classified as "moderate," and 65% of outcomes were rated as "very low."
CONCLUSION: Patients with inflammatory bowel diseases had a higher risk of adverse health outcomes and further studies should be conducted to draw firmer conclusions.
Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Ulcerative colitis

Mesh:

Year:  2021        PMID: 33551353     DOI: 10.1016/j.dld.2021.01.018

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

Review 1.  Medications for Multiple Sclerosis and Risk of Malignancy: What Next?

Authors:  Daniel B Horton; Anthony T Reder
Journal:  Neurotherapeutics       Date:  2021-08-18       Impact factor: 6.088

Review 2.  Influence of Natural Polysaccharides on Intestinal Microbiota in Inflammatory Bowel Diseases: An Overview.

Authors:  Qi Li; Linyan Li; Qiqiong Li; Junqiao Wang; Shaoping Nie; Mingyong Xie
Journal:  Foods       Date:  2022-04-09

3.  Inflammatory bowel disease and cardiovascular disease: A two-sample Mendelian randomization analysis.

Authors:  Kaiwen Wu; Aoshuang Li; Lei Liu; Tao Shu; Demeng Xia; Xiaobin Sun
Journal:  Front Cardiovasc Med       Date:  2022-09-02

4.  Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Bo Qiu; Jia-Xu Liang; Cong Li
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.